Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
/PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that the company granted equity awards to...
Stay updated with breaking news from Inducement Plan. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that the company granted equity awards to...
/PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that the company granted equity awards to...
EMERYVILLE, Calif.--(BUSINESS WIRE)--#earnings--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that on October 3, 2022, the Human Capital Management and Compensation Committee of Ligand’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 10,770 shares of its...
NEW YORK, Sept. 29, 2022 /PRNewswire/ -- LivePerson, Inc. (Nasdaq: LPSN) is providing confirmatory notice, pursuant to the requirements of Nasdaq Listing Rule 5635(c)(4), of recent grants of equity-based incentive awards that LivePerson made under its I...
/PRNewswire/ -- LivePerson, Inc. (Nasdaq: LPSN) is providing confirmatory notice, pursuant to the requirements of Nasdaq Listing Rule 5635(c)(4), of recent...